The post Johnson & Johnson – World Class Benchmarking appeared first on Become a Better Investor. Company: Johnson & Johnson Bloomberg ticker: JNJ US Market cap: US$383,813m Background: Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s primary focus is products related to human health and well-being. World Class Benchmarking of Johnson & Johnson   Profitable Growth rank of 1 was up compared to the prior period’s 2nd rank This is World Class performan ..read more

The post Sinovac Biotech – World Class Benchmarking appeared first on Become a Better Investor. Company: Sinovac Biotech Limited Bloomberg ticker: SVA US Market cap: US$640m Background: Sinovac Biotech Limited is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases World Class Benchmarking of Sinovac Biotech   Profitable Growth rank of 8 was same compared to the prior period’s 8th rank This is below average performance compared to 400 medium ..read more

The post Pfizer – World Class Benchmarking appeared first on Become a Better Investor. Company: Pfizer Incorporated Bloomberg ticker: PFE US Market cap: US$153,536m Background: Pfizer Incorporated is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. World Class Benchmarking of Pfizer   Profitable Growth rank of 5 was down compared to the prior period’s 1st rank This is average performance compared to 380 large Health Care companies worldwide Profi ..read more

The post AstraZeneca – World Class Benchmarking appeared first on Become a Better Investor. Company: AstraZeneca PLC Bloomberg ticker: AZN LN Market cap: US$200,088m Background: AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. World Class Benchmarking of AstraZeneca   Profitable Growth rank of 4 was down compared to the prior period’s 3rd rank Thi ..read more

The post Become a Better Investor Newsletter – 20 April 2024 appeared first on Become a Better Investor. Noteworthy this week The bond trade hasn’t played out S&P 500 is down in terms of gold Manager allocates 70% of its AUM to cash Bitcoin is 3x-levered NASDAQ Fast food outpaces inflation The bond trade hasn’t played out: In December 2023, BofA published its Global Fund Manager Survey, showing that fund managers were the most bullish on rates since they started asking the question 20 years ago. The Bloomberg Global Aggregate Bond Index is down 4% 2024YTD. 5/15 Since it was a survey of ..read more

The post Goal Setting Is Often An Act of Desperation: Part 2 appeared first on Become a Better Investor. The post was originally published here. Goal Setting Is Often An Act of Desperation: Part 2 “Do you struggle to meet your goals or targets? Find out how you can change your thinking about goals and your process for setting them so you can keep moving forward. In this episode, John Dues and host Andrew Stotz discuss the first five of John’s 10 Key Lessons for Data Analysis.” Get the full show notes here.  Listen on Apple Podcasts o ..read more

The post Sinopharm Group – World Class Benchmarking appeared first on Become a Better Investor. Company: Sinopharm Group Company Limited Bloomberg ticker: 1099 HK Market cap: US$8,554m Background: Sinopharm Group Company Limited is the largest pharmaceutical distributor in China by revenue. It researches and develops, manufactures and markets medicines, ranging from traditional Chinese medicines to prescription and over-the-counter healthcare products and medical devices. The company serves hospitals, clinics, and drug stores. World Class Benchmarking of Sinopharm Group   Profitable Gro ..read more

The post Prada SpA – World Class Benchmarking appeared first on Become a Better Investor. Company: Prada SpA Bloomberg ticker: 1913 HK Market cap: US$18,067m Background: Prada SpA is an Italy-based company in the fashion industry. It is a parent company of the Prada Group. The Company, along with its subsidiaries, designs, produces and distributes leather goods, handbags, clothing, eyewear, fragrances, footwear, and accessories. Prada SpA manufactures jackets, trousers, skirts, dresses, sweaters, and blouses, as well as perfumes and watches, among other things. World Class Benchmarking of Prad ..read more

The post Burberry Group – World Class Benchmarking appeared first on Become a Better Investor. Company: Burberry Group PLC Bloomberg ticker: BRBY LN Market cap: US$5,780m Background: Burberry Group PLC is a United Kingdom-based global luxury goods manufacturer, retailer, and wholesaler. The Company also licenses third parties to manufacture and distribute products using the Burberry trademarks. The Company’s segments include Retail/wholesale and Licensing. The Retail/wholesale segment is engaged in the sale of luxury goods through Burberry mainline stores, concessions, outlets, and digital com ..read more

The post Kering SA – World Class Benchmarking appeared first on Become a Better Investor. Company: Kering SA Bloomberg ticker: KER FP Market cap: US$55,083m Background: Kering SA is a France-based luxury group. The Group manages the development of a series of renowned Houses in Fashion, Leather Goods and Jewelry: Gucci, Saint Laurent, Bottega Veneta, Balenciaga, Alexander McQueen, Brioni, Boucheron, Pomellato, DoDo, Qeelin, as well as Kering Eyewear. World Class Benchmarking of Kering SA   Profitable Growth rank of 3 was down compared to the prior period’s 2nd rank This is above average ..read more